KRAS mutant bowel cancers segregate into two distinct subgroups

被引：0
|
作者：
Borowsky, J. [1 ,2 ,3 ]
Su, C. [1 ]
Fennell, L. [1 ]
Burge, M. [4 ]
Liu, J. [2 ]
Costa, A. Dias [8 ]
Ogino, S. [9 ,10 ,11 ]
Mckeone, D. [2 ]
Olsen, K. [2 ]
Badshah, J. [2 ]
Bond, C. [2 ]
Nowlan, B. [2 ]
Tria, S. [2 ]
Laki, V. [2 ]
Walker, N. [6 ]
Brown, I. [6 ]
Bettington, M. [6 ]
Leggett, B. [2 ,5 ]
Whitehall, V. [2 ,7 ]
机构：
[1] Queensland Hlth, Pathol Queensland, Brisbane, Qld, Australia
[2] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia
[3] Univ Queensland, Sch Med, Brisbane, Australia
[4] Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld, Australia
[5] Royal Brisbane & Womens Hosp, Dept Gastroenterol, Herston, Qld, Australia
[6] Envoi Pathol, Brisbane, Australia
[7] Queensland Hlth, Conjoint Internal Med Lab, Pathol Queensland, Brisbane, Qld, Australia
[8] Dana Farber Canc Inst, Boston, MA USA
[9] Harvard Med Sch, Dept Pathol, Program MPE Mol Pathol Epidemiol, Brigham & Womens Hosp, Boston, MA USA
[10] Broad Inst MIT & Harvard, Cambridge, MA USA
[11] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
239
引用
收藏
页码：28 / 29
页数：2
相关论文
共 50 条
  • [41] Stress granules are not present in Kras mutant cancers and do not control tumor growth
    Libert, Maxime
    Quiquempoix, Sophie
    Fain, Jean S.
    Pyr Dit Ruys, Sebastien
    Haidar, Malak
    Wulleman, Margaux
    Herinckx, Gaetan
    Vertommen, Didier
    Bouchart, Christelle
    Arsenijevic, Tatjana
    Van Laethem, Jean-Luc
    Jacquemin, Patrick
    EMBO REPORTS, 2024, 25 (11) : 4693 - 4707
  • [42] Not all KRAS-mutated pancreatic cancers are equal - mutant dosage matters
    Perry, Maria A.
    Varghese, Anna M.
    NATURE MEDICINE, 2025, 31 (02) : 390 - 391
  • [43] The ubiquitin protease UBP43 is a target for KRAS mutant lung cancers
    Mustachio, Lisa Maria
    Chinyengetere, Fadzai
    Lu, Yun
    Hu, Shanhu
    Kawakami, Masanori
    Tafe, Laura J.
    Danilov, Alexey
    Sekula, David J.
    Ma, Tian
    Freemantle, Sarah J.
    Dmitrovsky, Ethan
    CANCER RESEARCH, 2014, 74 (19)
  • [44] COMPARISON OF THE CHARACTERISTICS AND CLINICAL COURSE OF PATIENTS WITH METASTATIC KRAS MUTANT LUNG CANCERS
    Riely, Gregory
    Yu, Helena A.
    Sima, Camelia S.
    Shen, Ronglai
    Kass, Samantha L.
    Kris, Mark G.
    Ladanyi, Marc
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S504 - S505
  • [45] Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers
    Corcoran, Ryan B.
    ONCOLOGIST, 2016, 21 : S2 - S2
  • [46] Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers
    Moss, Deborah Y.
    McCann, Christopher
    Kerr, Emma M.
    SCIENCE SIGNALING, 2022, 15 (756)
  • [47] Dual inhibition of SUMOylation and MEK for MYC-expressing KRAS mutant cancers
    Kotani, Hiroshi
    Yano, Seiji
    CANCER SCIENCE, 2024, 115 : 395 - 395
  • [48] KRAS mutant epithelial ovarian carcinomas (EOC) represent distinct genomic genotypes
    Kilowski, K. A.
    Dietrich, M.
    Xiu, J.
    Jones, N.
    Powell, M.
    Turner, V. B. Galvan
    Erickson, B.
    Mutch, D.
    Thaker, P.
    ElNaggar, A.
    Dizon, D.
    Ahmad, S.
    Herzog, T.
    Korn, W. M.
    Holloway, R. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S632 - S632
  • [49] p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features
    Biganzoli, Elia
    Coradini, Danila
    Ambrogi, Federico
    Garibaldi, Jonhatan M.
    Lisboa, Paulo
    Soria, Daniele
    Green, Andrew R.
    Pedriali, Massimo
    Piantelli, Mauro
    Querzoli, Patrizia
    Demicheli, Romano
    Boracchi, Patrizia
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 172 - 179
  • [50] BRAIN MORPHOMETRY DISTINGUISHES TWO DISTINCT IBS SUBGROUPS
    Le, Clarence B.
    Mayer, Emeran A.
    Tillisch, Kirsten
    Labus, Jennifer S.
    GASTROENTEROLOGY, 2017, 152 (05) : S88 - S88
12345